Democracy In Action: Biotech Access To R&D Tools Spurs Licensing Deals

Drug licensing opportunities have increased 60% over the past five years, due in part to a "democratization" of technology previously available only to large pharma, Merck Senior VP-Worldwide Licensing & External Research Mervyn Turner, PhD, said